BR112017010775A2 - ?método para produzir um produto de conjugação enzimática? - Google Patents

?método para produzir um produto de conjugação enzimática?

Info

Publication number
BR112017010775A2
BR112017010775A2 BR112017010775A BR112017010775A BR112017010775A2 BR 112017010775 A2 BR112017010775 A2 BR 112017010775A2 BR 112017010775 A BR112017010775 A BR 112017010775A BR 112017010775 A BR112017010775 A BR 112017010775A BR 112017010775 A2 BR112017010775 A2 BR 112017010775A2
Authority
BR
Brazil
Prior art keywords
sequence
producing
polypeptide
conjugation product
enzyme conjugation
Prior art date
Application number
BR112017010775A
Other languages
English (en)
Inventor
Boenitz-Dulat Mara
SCHATTE Martin
Kratzsch Peter
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112017010775A2 publication Critical patent/BR112017010775A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/2207—Sortase A (3.4.22.70)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

na presente invenção é divulgado um método para produzir um produto de conjugação enzimática de dois polipeptídeos compreendendo a incubação de um primeiro polipeptídeo compreendendo a sequência de aminoácidos lpxtg (seq id no: 20, em que x pode ser qualquer resíduo de aminoácido), um segundo polipeptídeo possuindo uma sequencia de aminoácidos oligoalanina am (m = 2 (seq id no: 26) ou 3 (seq id no: 27) ou 4 (seq id no: 28) ou 5 (seq id no: 29)) em sua extremidade n-terminal, um terceiro polipeptídeo com atividade sortase que é derivada a partir da sortase a de staphylococcus aureus e a recuperação do conjugado a partir da mistura da reação e, assim, produzindo o produto de conjugação enzimática de dois polipeptídeos.
BR112017010775A 2014-12-17 2015-12-14 ?método para produzir um produto de conjugação enzimática? BR112017010775A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14198532 2014-12-17
PCT/EP2015/079617 WO2016096741A1 (en) 2014-12-17 2015-12-14 Novel methods for enzyme mediated polypeptide conjugation using sortase

Publications (1)

Publication Number Publication Date
BR112017010775A2 true BR112017010775A2 (pt) 2018-02-27

Family

ID=52338848

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017010775A BR112017010775A2 (pt) 2014-12-17 2015-12-14 ?método para produzir um produto de conjugação enzimática?

Country Status (11)

Country Link
US (1) US10190182B2 (pt)
EP (1) EP3233905B1 (pt)
JP (1) JP6618539B2 (pt)
KR (1) KR20170094216A (pt)
CN (1) CN107001447B (pt)
BR (1) BR112017010775A2 (pt)
CA (1) CA2966287A1 (pt)
MX (1) MX2017007503A (pt)
RU (1) RU2714963C2 (pt)
SG (1) SG11201704625UA (pt)
WO (1) WO2016096741A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106191015B (zh) * 2016-08-25 2019-09-13 北京大学 金黄色葡萄球菌分选酶a高效突变体
CN116888258A (zh) * 2021-02-04 2023-10-13 西湖生物医药科技(杭州)有限公司 修饰的红细胞及其治疗高尿酸血症和痛风的用途
WO2023134573A1 (en) * 2022-01-12 2023-07-20 Westlake Therapeutics (Shanghai) Co., Limited Modified cells and uses thereof
CN114487409B (zh) * 2022-04-14 2022-07-19 启德医药科技（苏州）有限公司 一种转肽酶活性的检测方法及检测试剂盒
CN116949004B (zh) * 2023-07-13 2024-04-09 苏州源启生物科技有限公司 一种转肽酶Sortase A及其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4150149A (en) 1976-11-29 1979-04-17 Professional Staff Association Of The Los Angeles County Harbor General Hospital Method and means for the early detection and diagnosis of certain types of cancers
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4361544A (en) 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US5342606A (en) 1984-10-18 1994-08-30 Board Of Regents, The University Of Texas System Polyazamacrocyclic compounds for complexation of metal ions
US5316757A (en) 1984-10-18 1994-05-31 Board Of Regents, The University Of Texas System Synthesis of polyazamacrocycles with more than one type of side-chain chelating groups
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5428139A (en) 1991-12-10 1995-06-27 The Dow Chemical Company Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
US5480990A (en) 1991-12-10 1996-01-02 The Dow Chemical Company Bicyclopolyazamacrocyclocarboxylic acid complexes for use as contrast agents
US5739294A (en) 1991-12-10 1998-04-14 The Dow Chemical Company Bicyclopol yazamacrocyclophosphonic acid complexes for use as contrast agents
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
PL174721B1 (pl) 1992-11-13 1998-09-30 Idec Pharma Corp Przeciwciało monoklonalne anty-CD20
US5462725A (en) 1993-05-06 1995-10-31 The Dow Chemical Company 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents
US5385893A (en) 1993-05-06 1995-01-31 The Dow Chemical Company Tricyclopolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5834456A (en) 1996-02-23 1998-11-10 The Dow Chemical Company Polyazamacrocyclofluoromonoalkylphosphonic acids, and their complexes, for use as contrast agents
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
BR0014480A (pt) 1999-10-04 2002-06-11 Medicago Inc Método para regular a transcrição de genes estranhos
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
SI2032606T1 (sl) * 2006-05-30 2014-02-28 Genentech, Inc. Protitelesa in imunokonjugati in njihove uporabe
WO2010087994A2 (en) * 2009-01-30 2010-08-05 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
ES2589769T3 (es) 2009-02-27 2016-11-16 Massachusetts Institute Of Technology Proteínas modificadas con alta afinidad por quelatos de DOTA
US10081684B2 (en) 2011-06-28 2018-09-25 Whitehead Institute For Biomedical Research Using sortases to install click chemistry handles for protein ligation
JP6203838B2 (ja) 2012-06-27 2017-09-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 少なくとも２つの異なる結合実体を含む、テーラーメイドの高度に選択的かつ多重特異的なターゲティング実体を選択および作製するための方法、ならびにその使用

Also Published As

Publication number Publication date
US20170292166A1 (en) 2017-10-12
JP2018500901A (ja) 2018-01-18
EP3233905A1 (en) 2017-10-25
RU2017122029A (ru) 2019-01-17
US10190182B2 (en) 2019-01-29
CN107001447B (zh) 2021-07-23
WO2016096741A1 (en) 2016-06-23
SG11201704625UA (en) 2017-07-28
MX2017007503A (es) 2017-10-04
JP6618539B2 (ja) 2019-12-11
EP3233905B1 (en) 2020-01-29
RU2714963C2 (ru) 2020-02-21
CA2966287A1 (en) 2016-06-23
KR20170094216A (ko) 2017-08-17
RU2017122029A3 (pt) 2019-07-17
CN107001447A (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
BR112017010775A2 (pt) ?método para produzir um produto de conjugação enzimática?
BR112017007202A2 (pt) receptores de célula t
NZ630536A (en) Therapeutic agent or prophylactic agent for dementia
PH12014501083A1 (en) Anticancer fusion protein
EA201401211A1 (ru) Улучшенные варианты фермента химозина
BR112015017797A2 (pt) celobio-hidrolase termoestável
BR112017020308A2 (pt) udp-glicosiltransferases
BR112013013548B8 (pt) Proteína de fusão anticancerígena
MX2013007872A (es) Proteina de fusion anticancer.
MX2020011083A (es) Proteina.
BR112018003594A2 (pt) cadeia pesada de imunoglobulina recombinante, anticorpos, método de produção de conjugado e conjugados
BR112014027991A2 (pt) agentes para neutralização de influenza
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
EA201591609A1 (ru) Варианты альфа-амилазы
MX2017015927A (es) Fragmentos mutantes de proteina ras.
PH12017502323A1 (en) Novel xylanase
PH12019501064A1 (en) Ras PROTIEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION
MX2020006328A (es) Composición inmunogénica.
BR112018012055A2 (pt) substrato de transglutaminase (tg) recombinante, método in vitro para marcar uma proteína de interesse, composição farmacêutica ou de diagnóstico e kit de diagnóstico
WO2017060318A3 (en) Kaurenoic acid hydroxylases
BR112013025975A2 (pt) proteína de fusão anticancerígena
SG195302A1 (en) Shk-based pharmaceutical compositions and methods of manufacturing and using the same
BR112017010888A2 (pt) método para produzir um produto de conjugação enzimática de três polipeptídeos
BR112016024970A2 (pt) microorganismos para produzir diamina e processo para produzir diamina usando os mesmos
BR112016024958A2 (pt) micro-organismos para produção de diamina e processo para produção de diamina utilizando os mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time